Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.

Whenever machine learning is applied to a given field of industry, defining the objective is one of the most salient questions. Just what are you trying to find out? In the biological sciences, that ...

Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies have signed deals with it to develop drugs using its AI-based strategy. The ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...